What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
-
Published:2018-05
Issue:5
Volume:29
Page:1249-1257
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Vale C.L.ORCID,
Fisher D.J.,
White I.R.,
Carpenter J.R.,
Burdett S.,
Clarke N.W.,
Fizazi K.,
Gravis G.,
James N.D.,
Mason M.D.,
Parmar M.K.B.,
Rydzewska L.H.,
Sweeney C.J.,
Spears M.R.,
Sydes M.R.ORCID,
Tierney J.F.
Subject
Oncology,Hematology
Reference24 articles.
1. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis;Rydzewska;Eur J Cancer,2017
2. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data;Vale;Lancet Oncol.,2016
3. Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial;Mason;J Clin Oncol.,2017
4. Simultaneous comparison of multiple treatments: combining direct and indirect evidence;Caldwell;BMJ.,2005
5. Network meta-analysis;White;Stata J,2015
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献